Fred Alger Management Adds $112M in Arrowhead Pharmaceuticals, Inc. ($ARWR)
Key Points
- Fred Alger Management changed its Arrowhead Pharmaceuticals, Inc. ($ARWR) stake by 82.4% last quarter, boosting to 3,342,493 shares worth $249.08 million.
- Wall Street's consensus rating on $ARWR is Buy and an average price target of $88.17.
- $ARWR last traded around $74.52.
Fred Alger Management increased its position in Arrowhead Pharmaceuticals, Inc. ($ARWR) by 82.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,342,493 shares of Arrowhead Pharmaceuticals, Inc. after buying 1,509,496 shares during the quarter. Fred Alger Management's holdings in Arrowhead Pharmaceuticals, Inc. were worth $249.08 million as of its most recent filing.
Arrowhead Pharmaceuticals, Inc. ($ARWR) Stock
Arrowhead Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.